Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma September 9, 2026 7:30 AM EDT
Company Participants
Thomas Civik – CEO & Chairman
Marsha Crochiere – Head of Translational Medicine & Research
Tom Dorney – SVP of Strategy & Financial Planning
Brian Freeman – Chief Program Officer
Conference Call Participants
Alan Ho
Jeffrey LaRosa – Leerink Partners LLC, Research Division
Bradley Canino – Guggenheim Securities, LLC, Research Division
Tianqi Hang – Wells Fargo Securities, LLC, Research Division
Samuel Slutsky – LifeSci Capital, LLC, Research Division
Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Leonid Timashev – RBC Capital Markets, Research Division
Presentation
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Pyxis Oncology MICVO Monotherapy Phase I Clinical Update. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would like now to turn the conference over to Tom Civik, Chief Executive Officer. Please go ahead.
Thomas Civik
CEO & Chairman
Good morning, and thanks for joining us today for our clinical update on MICVO. My name is Tom Civik, and I am the CEO here at Pyxis Oncology. I am so pleased to be here representing the extraordinary team at Pyxis Oncology. Before we begin, I want to share my deep thanks for the patients who put their trust in us, investigators who helped shape this program and a long list of partners who have supported and encouraged us through this important journey to unlock the potential of MICVO. And as you saw in the press release that went out this morning, we are thrilled to share with you the updated data from our Phase I study evaluating MICVO in second-line and beyond head and neck squamous cell carcinoma.
Please note that
Be the first to comment